Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in Japan / NCT06952530
Active, not recruiting Phase 3

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

NCT06952530 · tracked via the Priya Life Science Japan tracker
Sponsor
Eli Lilly and Company
Phase
Phase 3
Started
2025-04-30
Last updated
2026-05-29

Condition(s) studied

Hypertension

Investigational drug(s) / intervention(s)

Orforglipron →Placebo

Orforglipron: Administered orally

Placebo: placebo administered

Study summary

GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * refer to the GZPL master protocol study for screening eligibility. Exclusion Criteria: * refer to the GZPL master protocol study for screening eligibility.

Primary outcome measure(s)

  • Change from Baseline in office Systolic Blood Pressure (SBP) — Baseline to Week 36

Trial sites (99)

FacilityCityRegionStatus
Elite Clinical Studies, LLC Phoenix Arizona
Valley Clinical Trials, Inc. Covina California
Valley Clinical Trials, Inc. Northridge California
Chase Medical Research, LLC Waterbury Connecticut
Excel Medical Clinical Trials Boca Raton Florida
Care Access - Brandon Brandon Florida
Northeast Research Institute - Downtown Office Jacksonville Florida
Peace River Cardiovascular Center Port Charlotte Florida
East-West Medical Research Institute Honolulu Hawaii
Sinai Hospital Of Baltimore Baltimore Maryland
Ascension Saint Agnes Heart Care Baltimore Maryland
Lucida Clinical Trials New Bedford Massachusetts
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division Troy Michigan
StudyMetrix Research City of Saint Peters Missouri
Excel Clinical Research, LLC Las Vegas Nevada
Palm Research Center Sunset Las Vegas Nevada
Rochester Clinical Research, LLC Rochester New York
Remington-Davis, Inc Columbus Ohio
Advanced Research Institute - Tigard Tigard Oregon
Care Access - Mauldin Mauldin South Carolina
Dallas Heart and Vascular Consultants, PA Duncanville Texas
Texas Institute of Cardiology, PA McKinney Texas
North Hills Family Medicine/North Hills Medical Research North Richland Hills Texas
Advanced Research Institute Ogden Utah
Carient Heart & Vascular - Manassas Manassas Virginia
Health Research of Hampton Roads, Inc. Newport News Virginia
National Clinical Research, Inc Richmond Virginia
Eastside Research Associates Redmond Washington
Instituto Médico Especializado (IME) Buenos Aires Argentina
CIPREC Buenos Aires Argentina
CIPREC Buenos Aires Argentina
CEMEDIC Buenos Aires Argentina
Instituto de Investigaciones Clínicas Córdoba Córdoba Argentina
Centro de Investigaciones Clínicas Baigorria Granadero Baigorria Argentina
INECO Neurociencias Oroño Rosario Argentina
Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Medica Rosario Argentina
Santa Maria de la Salud Centro Medico San Isidro Argentina
Beijing Pinggu District Hospital Beijing China
China-Japan Union Hospital Changchun China
Changde First People's Hospital Changde China

+ 59 more sites — see the full list on the official registry below.

More Eli Lilly and Company trials in Japan

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults Recruiting
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors Active, not recruiting
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer Active, not recruiting
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease Active, not recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Recruiting

Other trials for the same condition

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients Active, not recruiting
HJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension Recruiting
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event Recruiting
A Clinical Study of the Paradise™ Renal Denervation System in Patients With Hypertension (RADIANCE-HTN DUO) Active, not recruiting
A Study of IBI3016 in Japanese Participants Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06952530 on ClinicalTrials.gov ↗ ← All trials in Japan